Evidence map›Paper›PMID 38189882›Full record

ArticleDoklady. Biochemistry and biophysics2024

Dichotomic Role of Low-Concentration EGCG in the Oxaliplatin Sensitivity of Colorectal Cancer Cells.

Zhiyong Wang, Min Wang, Jiahao Huang, Mao Lin, Pei Wei

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Zhiyong WangDepartment of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
Min WangDepartment of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Jiahao HuangDepartment of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
Mao LinDepartment of Physiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China.
Pei WeiDepartment of Immunology, Zhuhai Campus of Zunyi Medical University, Zhuhai, China. wpwpwp6@126.com.
Zunyi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although epigallocatechin-3-gallate (EGCG) can potentiate chemotherapeutic drugs at high concentrations, its clinical translation is hampered by exceeding possible concentration thresholds. This study proposes a dichotomous use of low-concentration EGCG in chemotherapy. During the first cycle of combined treatment with oxaliplatin (OXA), low-concentration EGCG antagonized the cytotoxic effect of OXA on colorectal cancer (CRC) cells. However, when OXA was subsequently administered, the sensitivity of CRC cells markedly increased. Although low-concentration EGCG counteracted OXA, it reduced the OXA-induced secretion of vascular endothelial growth factor by tumor cells, thereby contributing to the increase in the sensitivity of tumor cells to the second round of OXA treatment. Therefore, low-concentration EGCG showed potential as a viable adjunct to modulate chemosensitivity in CRC.

Indexed as

Antineoplastic AgentsColorectal NeoplasmsCatechinCell Line, TumorHumansOxaliplatinVascular Endothelial Growth Factor AAntineoplastic AgentsCatechinepigallocatechin gallateOxaliplatinVascular Endothelial Growth Factor Acolorectal cancerepigallocatechin-3-gallateoxaliplatinVascular endothelial growth factor

Identifiers

PMID38189882
PMCPMC11021325
OpenAlexW4390676158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.